TWO DISEASES: ONE DRUG (ACE INHIBITORS IN THE TREATMENT OF HYPERTENSION IN PATIENTS WITH CORONARY HEART DISEASE)
- Authors: Melnik M.1, Uvarovskaya B.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 25, No 3 (2014)
- Pages: 26-30
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115891
- ID: 115891
Cite item
Open Access
Access granted
Abstract
Numerous controlled trials have demonstrated that ACE inhibitors are highly effective in reducing the cardiovascular risk in the treatment of patients with hypertension and coronary heart disease (CHD). The benefits of Prestarium A are the stabilization of its antihypertensive effect during 24 hours, including morning hours when a rapid elevation of blood pressure and high circadian frequency of ischemic episodes double the risk of complications in these categories of patients, as well as high tissue selectivity and good tolerability, which enables its recommendation for the treatment of patients with hypertension and CHD.
Full Text
About the authors
M. Melnik
I.M. Sechenov First Moscow State Medical University
Email: melnik.m.v@gmail.com
Professor
B. Uvarovskaya
I.M. Sechenov First Moscow State Medical UniversityMD
References
- Mancia G., Fagard R., Narkieewicz R. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidrlines for the management of arterial hypertension // J. Hypertyens. - 2013; 31: 1281-357.
- Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония в XXI веке: достижения, проблемы, перспективы // Кардиология. - 2013; 12: 272.
- Heran B., Wong M., Heran I. et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. The Cochrane Collaboration // Cochrane database System. Rev. - 2008: 4: CD003823. DOL:10.1002/14651858.CD003823.pub2
- Ferrari R., Pasanisi G., Notarstefano P. et al. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril // Exp. Rev. Cardiovasc. Ther. - 2005; 3: 15-29.
- Efficacy of Perindopril in reduction of cardiovascular events amrong patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA study) // Lancet. - 2003; 362: 782-8.
- Daly C., Fox K., Remme W. et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy // Eur. Heart. J. - 2005; 26: 1369-78.
- Ceconi C., Fox K., Remme W. et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT // Casrdiovasc. Res. - 2007; 73 (1): 237-46.
- Bots M., Remme J., Luscher T. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial // Casrdiovasc. Drug. Ther. - 2007; 21 (4): 269-79.
- Rodriguez-Granillo G., Vos J., Bruining N. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study) // Am. J. Cardiol. - 2007; 100 (2): 159-63.
- Карпов Ю.А., Шальнова С.А., Деев А.Д. Результаты клинического этапа национальной программы ПРЕМЬЕРА // Прогресс в кардиол. - 2006; 2: 1-4.
- VanVark L., Bertrand M., Akkerhuis K. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension a meta-analysis of randomized clinical trials of rennin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart J. - 2012; 33: 2088-97.
- Tsoukas G., Anand S., Yang K. et al. For the CONFIDENCE Investigators // Eur. Heart J. - 2010; 31 (23): 2888-96.
Supplementary files
